inozyme.com - INZY Short-Term Debt to Capital

Inozyme Pharma, Inc. (INZY) develops medications for individuals with genetic metabolic disorders, possessing immense market potential due to a lack of alternatives. The company is currently in the clinical testing stage, where expanding its product portfolio is driving an increase in costs. The confirmed price history on the GURU.Markets chart reflects a value of 0.81, while the success of its tissue calcification therapy is supported by partnerships with leading scientific centers.

To identify drivers of financial stability, it is essential for investors to analyze the short-term debt-to-equity ratio, calculated as the ratio of liabilities maturing within one year to equity, which reflects a company's reliance on short-term financing—a factor that is critical for Inozyme Pharma, Inc. (INZY) in securing costly international raw material supply chains and supporting its global network of biohubs.